Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience.
Journal: Hematology (Amsterdam, Netherlands)
Published: September 01, 2026
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.
Journal: Advances in therapy
Published: September 02, 2025
Relative Effectiveness of Talquetamab Versus Real-World Physician's Choice Treatment Regimens in Patients With Relapsed/Refractory Multiple Myeloma: Updated Results From an Indirect Treatment Comparison.
Journal: Clinical lymphoma, myeloma & leukemia
Published: August 18, 2025
Talquetamab in Japanese patients with relapsed/refractory multiple myeloma in the MonumenTAL-1 study.
Journal: International journal of hematology
Published: June 24, 2025
Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study.
Journal: Haematologica
Published: September 10, 2020
THE PRESENT AND FUTURE OF THE MASS SPECTROMETRY-BASED INVESTIGATION OF THE EXOSOME LANDSCAPE.
Journal: Mass spectrometry reviews
Published: October 16, 2019
Surgical stress and cancer progression: the twisted tango.
Journal: Molecular cancer
Published: June 18, 2019
Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 30, 2018
Anabolic steroid users' misuse of non-traditional prescription drugs.
Journal: Research in social & administrative pharmacy : RSAP
Published: March 30, 2018
Epigenetics in ovarian cancer: premise, properties, and perspectives.
Journal: Molecular cancer
Published: December 23, 2017
The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts.
Journal: Genome biology
Published: October 19, 2017
Last Updated: 09/26/2026